<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03230162</url>
  </required_header>
  <id_info>
    <org_study_id>Ain shams university maternity</org_study_id>
    <nct_id>NCT03230162</nct_id>
  </id_info>
  <brief_title>Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment</brief_title>
  <official_title>Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      comparing the effect of using sildenafil citrate and LMWH in treatment of cases of IUGR due
      to placental insufficiency
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hundred pregnant women with documented intrauterine growth restriction due to placental
      insufficiency at 28-35 weeks of gestation will be distributed into two groups:

        -  Group S: 50 women will receive Sildenafil citrate 25 mg tab 3 times daily.

        -  Group H: 50 women will receive single dose of LMWH subcutaneous daily.

      Both groups will undergo strict fetal surveillance in the form of:

      Umbilical artery Doppler (UAD) is the primary surveillance tool in the FGR fetus:

      middle cerebral artery (MCA) Doppler, ultrasound for (AC, EFW, and deepest vertical pocket
      (DVP) for amniotic fluid) and non stress test and Biophysical profile (BPP)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neonatal birth weight in grams</measure>
    <time_frame>At time of Delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in Doppler velocity indices,</measure>
    <time_frame>24 week till 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal growth velocity</measure>
    <time_frame>weekly till time of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery,</measure>
    <time_frame>at time of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR score</measure>
    <time_frame>at 1 and 5 min of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal complication rates</measure>
    <time_frame>The first 28 day of delivery</time_frame>
    <description>respiratory distress syndrome, intraventricular hemorrhage (IVH), neonatal necrotizing enterocolitis (NEC), neonatal anemia, and neonatal blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal ICU admission rate</measure>
    <time_frame>The first 28 day of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the interval between the diagnosis and delivery</measure>
    <time_frame>at time of delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Fetal Growth Abnormality</condition>
  <condition>Fetal Growth Restriction</condition>
  <arm_group>
    <arm_group_label>sildenafil citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 pregnant female will be treated with sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low molecular weight heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 pregnant female will be treated with a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery according to body weight as follow &lt; 50 kg 3500 units daily 50-90 kg 4500 units daily 91-130 kg 7000 units daily 131-170 kg 9000 units daily &gt; 170 kg 75 u/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery</description>
    <arm_group_label>sildenafil citrate</arm_group_label>
    <other_name>Silden EIPICO co.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low molecular weight heparin</intervention_name>
    <description>a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery</description>
    <arm_group_label>low molecular weight heparin</arm_group_label>
    <other_name>tinzaparin</other_name>
    <other_name>Innohep LEO pharmaceutical products</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maternal age between 20-35 years.

          -  Being at a gestational age 28-35wks.

          -  Singleton pregnancy.

          -  Fetal growth restriction diagnosed by ultrasound with estimated fetal weight below the
             10th percentile, and/or fetal abdominal circumference at or below the tenth
             percentile.

        Exclusion Criteria:

          -  Maternal age less than 20 years or more than 35 years.

          -  Undetermined gestational age.

          -  Multiple gestation.

          -  Chronic diseases with pregnancy e.g. Chronic hypertension, diabetes type 1 or 2.

          -  Etiologies of FGR other than placental insufficiency as fetal malformations,
             aneuploidy or infections.

          -  Suspected fetal compromise requiring emergency delivery.

          -  Any contraindication to the use of sildenafil e.g. known significant maternal cardiac
             disease, left ventricular outflow tract obstruction, concomitant treatment with
             nitrates or previous allergy to sildenafil.

          -  Any contraindication to the use of LMWH e.g. known bleeding disorder, active antenatal
             bleeding or at increased risk of major hemorrhage (e.g. placenta praevia),
             thrombocytopenia, severe renal or hepatic disease.

          -  Drug or alcohol abuse.

          -  Patient refusing to participate in the study or unable to consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Radwa R Ali, MD</last_name>
    <phone>01283492979</phone>
    <phone_ext>+202</phone_ext>
    <email>radwaebed@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AinShams university maternity hospital</name>
      <address>
        <city>Cairo</city>
        <zip>02</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radwa R Ali, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2017</study_first_submitted>
  <study_first_submitted_qc>July 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>July 23, 2017</last_update_submitted>
  <last_update_submitted_qc>July 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Radwa Rasheedy Ali</investigator_full_name>
    <investigator_title>lecturer of obstetrics and gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

